ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Barclays PLC

Barclays PLC raised its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 41.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 158,180 shares of the company's stock after purchasing an additional 46,514 shares during the period. Barclays PLC owned 0.16% of ARS Pharmaceuticals worth $1,669,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alliancebernstein L.P. grew its holdings in ARS Pharmaceuticals by 5,168.4% in the 4th quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company's stock valued at $40,942,000 after buying an additional 3,807,074 shares in the last quarter. Raymond James Financial Inc. purchased a new position in ARS Pharmaceuticals during the fourth quarter worth about $6,576,000. Peregrine Capital Management LLC purchased a new position in ARS Pharmaceuticals during the fourth quarter worth about $4,469,000. Royce & Associates LP boosted its holdings in ARS Pharmaceuticals by 34.4% in the 4th quarter. Royce & Associates LP now owns 929,613 shares of the company's stock valued at $9,807,000 after purchasing an additional 238,158 shares during the last quarter. Finally, Levin Capital Strategies L.P. grew its stake in shares of ARS Pharmaceuticals by 56.2% in the 4th quarter. Levin Capital Strategies L.P. now owns 467,627 shares of the company's stock valued at $4,933,000 after buying an additional 168,201 shares during the period. Institutional investors and hedge funds own 68.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Leerink Partners upped their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Monday, January 13th. Oppenheimer started coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They set an "outperform" rating and a $40.00 price target for the company. Raymond James boosted their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a "strong-buy" rating in a report on Tuesday, January 14th. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They set a "sector outperform" rating and a $30.00 target price for the company. Finally, William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $31.00.

Insider Activity at ARS Pharmaceuticals

In other news, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares in the company, valued at approximately $107,744. This trade represents a 56.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Laura Shawver sold 50,002 shares of the company's stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $12.30, for a total transaction of $615,024.60. Following the sale, the director now owns 210,346 shares in the company, valued at $2,587,255.80. The trade was a 19.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 109,602 shares of company stock worth $1,311,041. Company insiders own 40.10% of the company's stock.

ARS Pharmaceuticals Stock Down 5.4 %

NASDAQ:SPRY traded down $0.76 on Wednesday, reaching $13.26. 712,625 shares of the company's stock were exchanged, compared to its average volume of 1,180,085. The business has a fifty day moving average of $12.96 and a 200-day moving average of $13.01. ARS Pharmaceuticals, Inc. has a 52-week low of $7.55 and a 52-week high of $18.51. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -26.06 and a beta of 0.84.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.56. The business had revenue of $86.58 million during the quarter, compared to analysts' expectations of $15.46 million. As a group, equities analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.